These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 21568825)

  • 1. Pharmacogenomics and adverse drug reactions: the case of statins.
    Giorgi MA; Caroli C; Arazi HC; Di Girolamo G
    Expert Opin Pharmacother; 2011 Jul; 12(10):1499-509. PubMed ID: 21568825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.
    Hubáček JA; Dlouhá D; Adámková V; Zlatohlavek L; Viklický O; Hrubá P; Češka R; Vrablík M
    Med Sci Monit; 2015 May; 21():1454-9. PubMed ID: 25992810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomics and drug toxicity.
    Nakamura Y
    N Engl J Med; 2008 Aug; 359(8):856-8. PubMed ID: 18650508
    [No Abstract]   [Full Text] [Related]  

  • 4. SLCO1B1 variants and statin-induced myopathy.
    Vladutiu GD; Isackson PJ
    N Engl J Med; 2009 Jan; 360(3):304. PubMed ID: 19144951
    [No Abstract]   [Full Text] [Related]  

  • 5. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
    Brunham LR; Lansberg PJ; Zhang L; Miao F; Carter C; Hovingh GK; Visscher H; Jukema JW; Stalenhoef AF; Ross CJ; Carleton BC; Kastelein JJ; Hayden MR
    Pharmacogenomics J; 2012 Jun; 12(3):233-7. PubMed ID: 21243006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Interindividual differences in the response to statin therapy and gene polymorphisms related to myopathy during statin therapy].
    Dendramis G
    G Ital Cardiol (Rome); 2011 Mar; 12(3):182-5. PubMed ID: 21560474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacogenetic analysis can predict adverse effects of statins].
    Garwicz D; Wadelius M
    Lakartidningen; 2013 May 7-21; 110(19-20):951-2. PubMed ID: 23745502
    [No Abstract]   [Full Text] [Related]  

  • 8. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.
    Wilke RA; Ramsey LB; Johnson SG; Maxwell WD; McLeod HL; Voora D; Krauss RM; Roden DM; Feng Q; Cooper-Dehoff RM; Gong L; Klein TE; Wadelius M; Niemi M;
    Clin Pharmacol Ther; 2012 Jul; 92(1):112-7. PubMed ID: 22617227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case-Control Studies.
    Hou Q; Li S; Li L; Li Y; Sun X; Tian H
    Medicine (Baltimore); 2015 Sep; 94(37):e1268. PubMed ID: 26376374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SLCO1B1 variants and statin-induced myopathy--a genomewide study.
    ; Link E; Parish S; Armitage J; Bowman L; Heath S; Matsuda F; Gut I; Lathrop M; Collins R
    N Engl J Med; 2008 Aug; 359(8):789-99. PubMed ID: 18650507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacogenetics of statin therapy: when the body aches, the mind will follow.
    Rossi JS; McLeod HL
    J Am Coll Cardiol; 2009 Oct; 54(17):1617-8. PubMed ID: 19833261
    [No Abstract]   [Full Text] [Related]  

  • 12. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.
    Ramsey LB; Johnson SG; Caudle KE; Haidar CE; Voora D; Wilke RA; Maxwell WD; McLeod HL; Krauss RM; Roden DM; Feng Q; Cooper-DeHoff RM; Gong L; Klein TE; Wadelius M; Niemi M
    Clin Pharmacol Ther; 2014 Oct; 96(4):423-8. PubMed ID: 24918167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.
    Generaux GT; Bonomo FM; Johnson M; Doan KM
    Xenobiotica; 2011 Aug; 41(8):639-51. PubMed ID: 21425956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Researchers worry about myopathy risk for patients taking high-dose simvastatin.
    Mitka M
    JAMA; 2009 Jan; 301(3):261-2. PubMed ID: 19155447
    [No Abstract]   [Full Text] [Related]  

  • 15. Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study.
    Puccetti L; Ciani F; Auteri A
    Atherosclerosis; 2010 Jul; 211(1):28-9. PubMed ID: 20347093
    [No Abstract]   [Full Text] [Related]  

  • 16. Statins and skeletal muscles toxicity: from clinical trials to everyday practice.
    Norata GD; Tibolla G; Catapano AL
    Pharmacol Res; 2014 Oct; 88():107-13. PubMed ID: 24835295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The SLCO1B1*5 genetic variant is associated with statin-induced side effects.
    Voora D; Shah SH; Spasojevic I; Ali S; Reed CR; Salisbury BA; Ginsburg GS
    J Am Coll Cardiol; 2009 Oct; 54(17):1609-16. PubMed ID: 19833260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Use of pharmacogenetic testing to prevent adverse drug reactions during statin therapy].
    Rumyantsev NA; Kukes VG; Kazakov RE; Rumyantsev AA; Sychev DA
    Ter Arkh; 2017; 89(1):82-87. PubMed ID: 28252633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy.
    Danik JS; Chasman DI; MacFadyen JG; Nyberg F; Barratt BJ; Ridker PM
    Am Heart J; 2013 Jun; 165(6):1008-14. PubMed ID: 23708174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review.
    Canestaro WJ; Austin MA; Thummel KE
    Genet Med; 2014 Nov; 16(11):810-9. PubMed ID: 24810685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.